Atlas Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-7,758
| Closed | -$5.99M | – | 1089 |
|
|
2026
Q1 | $5.99M | Hold |
7,758
| – | – | 0.69% | 40 |
|
|
2025
Q4 | $5.99M | Buy |
+7,758
| New | +$5.27M | 0.67% | 41 |
|
|
2025
Q2 | $4.07M | Sell |
7,758
-700
| -8% | -$391K | 0.5% | 49 |
|
|
2025
Q1 | $5.36M | Sell |
8,458
-8
| -0.1% | -$5.5K | 0.67% | 42 |
|
|
2024
Q4 | $6.03M | Buy |
8,466
+8,318
| +5,620% | +$6.98M | 0.77% | 37 |
|
|
2024
Q3 | $156K | Sell |
148
-8,334
| -98% | -$9.27M | 0.02% | 416 |
|
|
2024
Q2 | $8.91M | Buy |
8,482
+8,331
| +5,517% | +$8.08M | 1.16% | 21 |
|
|
2024
Q1 | $145K | Sell |
151
-8,334
| -98% | -$7.92M | 0.02% | 424 |
|
|
2023
Q4 | $7.45M | Hold |
8,485
| – | – | 1.08% | 22 |
|
|
2023
Q3 | $6.98M | Hold |
8,485
| – | – | 1.15% | 21 |
|
|
2023
Q2 | $6.1M | Sell |
8,485
-2
| -0% | -$1.54K | 0.92% | 25 |
|
|
2023
Q1 | $6.97M | Hold |
8,487
| – | – | 1.1% | 23 |
|
|
2022
Q4 | $6.12M | Hold |
8,487
| – | – | 1.03% | 24 |
|
|
2022
Q3 | $5.85M | Sell |
8,487
-15
| -0.2% | -$9.44K | 1.06% | 21 |
|
|
2022
Q2 | $5.03M | Buy |
8,502
+20
| +0.2% | +$13K | 0.85% | 26 |
|
|
2022
Q1 | $5.92M | Buy |
8,482
+9
| +0.1% | +$5.69K | 0.92% | 29 |
|
|
2021
Q4 | $5.35M | Hold |
8,473
| – | – | 0.8% | 31 |
|
|
2021
Q3 | $5.13M | Hold |
8,473
| – | – | 0.82% | 30 |
|
|
2021
Q2 | $4.73M | Hold |
8,473
| – | – | 0.79% | 29 |
|
|
2021
Q1 | $4.01M | Sell |
8,473
-296
| -3% | -$144K | 0.78% | 29 |
|
|
2020
Q4 | $4.24M | Sell |
8,769
-340
| -4% | -$184K | 0.89% | 27 |
|
|
2020
Q3 | $5.1M | Buy |
9,109
+530
| +6% | +$321K | 1.21% | 16 |
|
|
2020
Q2 | $5.35M | Buy |
8,579
+121
| +1% | +$68.7K | 1.26% | 12 |
|
|
2020
Q1 | $4.13M | Hold |
8,458
| – | – | 1.23% | 14 |
|
|
2019
Q4 | $3.18M | Hold |
8,458
| – | – | 0.79% | 24 |
|
|
2019
Q3 | $2.35M | Hold |
8,458
| – | – | 0.71% | 23 |
|
|
2019
Q2 | $2.65M | Hold |
8,458
| – | – | 0.87% | 16 |
|
|
2019
Q1 | $3.47M | Hold |
8,458
| – | – | 1.25% | 11 |
|
|
2018
Q4 | $3.16M | Hold |
8,458
| – | – | 1.27% | 10 |
|
|
2018
Q3 | $3.41M | Hold |
8,458
| – | – | 1.14% | 15 |
|
|
2018
Q2 | $3.09M | Hold |
8,458
| – | – | 1.1% | 14 |
|
|
2018
Q1 | $2.91M | Buy |
+8,458
| New | +$2.94M | 0.89% | 15 |
|
Other funds holding REGN
Atlas Capital Advisors's REGN Position: Q2 2026 in Review
Atlas Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 7,758 shares — an estimated $5.99M sold.
Atlas Capital Advisors first reported a position in REGN in Q1 2018 and held it in 32 quarters. The position peaked at $8.91M in Q2 2024. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Atlas Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Atlas Capital Advisors sold 7,758 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $5.99M.
- Atlas Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2018 and held it in 32 quarters.
- Atlas Capital Advisors's Regeneron Pharmaceuticals position peaked at $8.91M in Q2 2024.
- 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.